GSK and AZ-Merck's PARP drugs scored at ESMO. But where does that leave Clovis’ Rubraca?

2nd October 2019 Uncategorised 0

After the PARP inhibitor showdown at ESMO this weekend between GlaxoSmithKline’s Zejula and AstraZeneca and Merck & Co.’s Lynparza, industry watchers declared it difficult to tell who won this round of the data battle. But another company should definitely feel the pressure, analysts say, and that’s Clovis Oncology.

More: GSK and AZ-Merck's PARP drugs scored at ESMO. But where does that leave Clovis’ Rubraca?
Source: fierce